A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Spain- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Spain13 clinical trials in Salt, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
SpainThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on relapsing-remitting multiple sclerosis and its treatment approaches, including comparative studies of novel therapies and established medications.
Multiple innovative therapies are being evaluated to improve patient outcomes and reduce disease progression.
Dedicated research into Primary Progressive Multiple Sclerosis (PPMS), exploring new therapeutic options through targeted treatment approaches.
Studies focus on developing treatments to delay disability progression in PPMS patients.
Research addressing specific medical conditions including severe primary hand hyperhidrosis and pregnancy-related conditions such as nausea and vomiting.
Clinical investigations aim to enhance treatment options and patient comfort across various conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.